<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388386</url>
  </required_header>
  <id_info>
    <org_study_id>PROTEUS-LVAD</org_study_id>
    <nct_id>NCT02388386</nct_id>
  </id_info>
  <brief_title>Monitoring Medication Adherence in Left Ventricular Assist Device Recipients</brief_title>
  <official_title>Pilot Study of Wireless Observed Therapy With an Ingestible Micro-Sensor Among Patients With Heart Failure and Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scripps Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to develop a novel and wireless method for monitoring medication&#xD;
      adherence among heart failure patients with left ventricular assist devices (LVADs). Proteus&#xD;
      Digital™ has developed an ingestible and bio-absorbable micro-sensor as a strategy to monitor&#xD;
      medication compliance. The edible sensor has at its core a silicon-based integrated circuit&#xD;
      measuring 1.0 mm x 0.45 mm and is imbedded on a pill. Once ingested, this circuit is&#xD;
      activated by gastric acid resulting in an electrochemical redox reaction and an electrical&#xD;
      charge that is transmitted to a patch worn over the abdomen and wirelessly to a portable&#xD;
      device such as a smart phone. This strategy of medication adherence differs from conventional&#xD;
      adherence monitoring including pill counting and patient-recall by precisely tracking&#xD;
      medication ingestion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives are to assess the efficacy and safety of the Proteus Digital™ micro-sensor in&#xD;
      an exploratory investigation among heart failure patients with LVADs. Medication adherence,&#xD;
      specifically to anticoagulation is critically important in the post-implant period to&#xD;
      maintain LVAD function and to decrease thromboembolic complications; however, commonly&#xD;
      results in significant bleeding resulting in significant morbidity and mortality. In&#xD;
      addition, the anticipated degree of anticoagulation is unpredictable after LVAD implantation&#xD;
      due to factors related to changes in hepatic blood flow and endothelial dysfunction.&#xD;
      Enrolling 10 patients will provide results into the function of micro-sensor and to provide a&#xD;
      preliminary assessment of sensor-based activity, signal strength and signal duration in LVAD&#xD;
      recipients. Participants will be enrolled during an in-patient hospitalization to assess the&#xD;
      efficacy and safety of the device in a monitored setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>System Performance - Positive Detection Accuracy</measure>
    <time_frame>30 minutes after ingestion</time_frame>
    <description>Primary outcome measure of system performance will be estimated by the positive detection accuracy, defined as the number of ingestible sensors detected divided by those ingested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From time of ingestion to 30 minutes after ingestion</time_frame>
    <description>Specific safety metrics will consist of the following composite outcome:&#xD;
Safety as measured by vital signs&#xD;
Cardiac rhythm monitoring review for arrhythmias&#xD;
LVAD device interrogation for changes in device parameters&#xD;
Implantable cardioverter defibrillator interrogation for arrhythmia occurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure</condition>
  <condition>Medication Compliance</condition>
  <arm_group>
    <arm_group_label>PROTEUS-SENSOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROTEUS-SENSOR</intervention_name>
    <description>An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.</description>
    <arm_group_label>PROTEUS-SENSOR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients undergoing LVAD implantation for end-stage heart failure or admitted from the&#xD;
        out-patient setting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to consistently consume oral intake&#xD;
&#xD;
          -  Hemodynamic instability defined as hypotension requiring intravenous vasoactive&#xD;
             medications or arrhythmias requiring intravenous antiarrhythmics or oral&#xD;
             antiarrhythmics for rhythm stabilization&#xD;
&#xD;
          -  Gastrointestinal bleeding requiring intravenous gastric acid secretion inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Bhavnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. Eur Heart J. 2016 May 7;37(18):1428-38. doi: 10.1093/eurheartj/ehv770. Epub 2016 Feb 11. Review.</citation>
    <PMID>26873093</PMID>
  </reference>
  <reference>
    <citation>DiCarlo LA, Weinstein RL, Morimoto CB, Savage GM, Moon GL, Au-Yeung K, Kim YA. Patient-Centered Home Care Using Digital Medicine and Telemetric Data for Hypertension: Feasibility and Acceptability of Objective Ambulatory Assessment. J Clin Hypertens (Greenwich). 2016 Sep;18(9):901-6. doi: 10.1111/jch.12787. Epub 2016 Feb 18.</citation>
    <PMID>26890041</PMID>
  </reference>
  <reference>
    <citation>DiCarlo L, Moon G, Intondi A, Duck R, Frank J, Hafazi H, Behzadi Y, Robertson T, Costello B, Savage G, Zdeblick M. A digital health solution for using and managing medications: wirelessly observed therapy. IEEE Pulse. 2012 Sep-Oct;3(5):23-6. doi: 10.1109/MPUL.2012.2205777.</citation>
    <PMID>23014703</PMID>
  </reference>
  <reference>
    <citation>Browne SH, Behzadi Y, Littlewort G. Let Visuals Tell the Story: Medication Adherence in Patients with Type II Diabetes Captured by a Novel Ingestion Sensor Platform. JMIR Mhealth Uhealth. 2015 Dec 31;3(4):e108. doi: 10.2196/mhealth.4292.</citation>
    <PMID>26721413</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>November 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2020</results_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <keyword>Mobile Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available upon request</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PROTEUS-SENSOR</title>
          <description>The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.&#xD;
PROTEUS-SENSOR: An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PROTEUS-SENSOR</title>
          <description>10 consecutive heart failure patients with continuous flow left ventricular devices</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>System Performance - Positive Detection Accuracy</title>
        <description>Primary outcome measure of system performance will be estimated by the positive detection accuracy, defined as the number of ingestible sensors detected divided by those ingested</description>
        <time_frame>30 minutes after ingestion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Outcome Measure</title>
            <description>Positive detection rate of 80%</description>
          </group>
        </group_list>
        <measure>
          <title>System Performance - Positive Detection Accuracy</title>
          <description>Primary outcome measure of system performance will be estimated by the positive detection accuracy, defined as the number of ingestible sensors detected divided by those ingested</description>
          <units>percentage of ingestions</units>
          <param>Number</param>
          <units_analyzed>Ingestions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Ingestions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Specific safety metrics will consist of the following composite outcome:&#xD;
Safety as measured by vital signs&#xD;
Cardiac rhythm monitoring review for arrhythmias&#xD;
LVAD device interrogation for changes in device parameters&#xD;
Implantable cardioverter defibrillator interrogation for arrhythmia occurrence</description>
        <time_frame>From time of ingestion to 30 minutes after ingestion</time_frame>
        <population>Specific safety metrics will consist of the following composite outcome:&#xD;
Safety as measured by vital signs&#xD;
Cardiac rhythm monitoring review for arrhythmias&#xD;
LVAD device interrogation for changes in device parameters&#xD;
Implantable cardioverter defibrillator interrogation for arrhythmia occurrence</population>
        <group_list>
          <group group_id="O1">
            <title>Vital Signs</title>
            <description>Safety as measured by vital signs</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Rhythm</title>
            <description>Cardiac rhythm monitoring for arrhythmias</description>
          </group>
          <group group_id="O3">
            <title>LVAD Device Interrogation</title>
            <description>Change in LVAD device parameters</description>
          </group>
          <group group_id="O4">
            <title>Implantable Cardioverter Defibrillator Interrogation</title>
            <description>Assessment of cardiac arrhythmias by ICD interrogation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Specific safety metrics will consist of the following composite outcome:&#xD;
Safety as measured by vital signs&#xD;
Cardiac rhythm monitoring review for arrhythmias&#xD;
LVAD device interrogation for changes in device parameters&#xD;
Implantable cardioverter defibrillator interrogation for arrhythmia occurrence</description>
          <population>Specific safety metrics will consist of the following composite outcome:&#xD;
Safety as measured by vital signs&#xD;
Cardiac rhythm monitoring review for arrhythmias&#xD;
LVAD device interrogation for changes in device parameters&#xD;
Implantable cardioverter defibrillator interrogation for arrhythmia occurrence</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours</time_frame>
      <desc>Adverse events defined as nausea, abdominal pain after ingestion, skin irritation due to the adhesive patch, arrhythmia</desc>
      <group_list>
        <group group_id="E1">
          <title>PROTEUS-SENSOR</title>
          <description>10 consecutive heart failure patients with continuous flow left ventricular devices</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sanjeev Bhavanni MD</name_or_title>
      <organization>Scripps Clinic Medical Group</organization>
      <phone>6196601842</phone>
      <email>bhavnani.sanjeev@scrippshealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

